tiprankstipranks
Analyst Profile
Followed by 172 other investors
.
Akash Tewari

Akash Tewari

Jefferies
Wall Street Analyst
Ranked #519 out of 8,047 Analysts on TipRanks (#711 out of 21,521 overall experts)

Success Rate

64%
42 out of 66 Profitable Transactions

Average Return

27.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Akash Tewari's ratings since 2018 and opened each position for the duration of 1 Year:
63.64% of your transactions would have been profitable with an average return of 27.6%

Stock Rating Distribution

102Ratings
77.45% Buy
17.65% Hold
4.90% Sell
Distribution of Akash Tewari's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Biontech Se Sponsored Adr
(BNTX)
Rating Type:Buy
Dates:Nov 05, 2019 - Nov 05, 2020
Gain:397.80%
The most profitable rating made by Akash Tewari

Akash Tewari's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Medicines Co
Buy
Initiated
100%
+341.80%
1
Teva Pharmaceutical
Hold
Initiated
$9.00
(-19.71% Downside)
0.00%
1
Arqule
Buy
Initiated
100%
+105.50%
1
Bausch Health Companies
Hold
Downgraded
100%
+25.70%
2
IGM Biosciences
Buy
Initiated
$75.00
(180.79% Upside)
100%
+137.10%
1
Alexion Pharmaceuticals
Buy
Initiated
100%
+97.60%
1
Vertex Pharmaceuticals
Buy
Initiated
$282.00
(-4.25% Downside)
100%
+5.00%
1
Viatris
Hold
Downgraded
0%
-7.10%
2
Acceleron Pharma
Hold
Initiated
0.00%
2
Zymeworks
Hold
Initiated
$32.00
(330.69% Upside)
100%
+26.40%
2
List of latest recommendations made by Akash Tewari. Click to expand and see Akash Tewari's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More